1. Home
  2. DTF vs NORD Comparison

DTF vs NORD Comparison

Compare DTF & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DTF Tax-Free Income 2028 Term Fund Inc.

DTF

DTF Tax-Free Income 2028 Term Fund Inc.

SELL

Current Price

$11.41

Market Cap

80.3M

Sector

Finance

ML Signal

SELL

NORD

Nordicus Partners Corporation Common Stock

N/A

Current Price

$2.65

Market Cap

95.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
DTF
NORD
Founded
N/A
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Professional Services
Sector
Finance
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
80.3M
95.5M
IPO Year
1995
2005

Fundamental Metrics

Financial Performance
Metric
DTF
NORD
Price
$11.41
$2.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.5K
★ 15.8K
Earning Date
01-01-0001
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.25
EPS
★ N/A
N/A
Revenue
N/A
★ $3,346.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$11.14
$2.14
52 Week High
$11.66
$5.28

Technical Indicators

Market Signals
Indicator
DTF
NORD
Relative Strength Index (RSI) 50.48 25.07
Support Level $11.39 $2.14
Resistance Level $11.57 $3.52
Average True Range (ATR) 0.08 0.55
MACD -0.00 -0.12
Stochastic Oscillator 19.35 22.56

Price Performance

Historical Comparison
DTF
NORD

About DTF DTF Tax-Free Income 2028 Term Fund Inc.

DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.

About NORD Nordicus Partners Corporation Common Stock

Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.

Share on Social Networks: